NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
14 trialsNCT02713373 2022-10-06
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT04315467 2022-06-16
Intraoperative Imaging of Pulmonary Nodules by SGM-101
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01335009 2021-09-01
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai Inc.
Phase 2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT02546284 2020-02-28
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Humanigen, Inc.
Phase 1 Completed
NCT00681993 2019-01-22
PBIC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00356460 2014-03-19
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Sanofi
Phase 1 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed
NCT00060138 2013-05-15
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Chugai Pharmaceutical
Phase 1/2 Completed
NCT00094653 2011-07-11
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT00142155 2011-06-27
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase NA Completed